Advertisement

Endocrine

, Volume 57, Issue 2, pp 308–313 | Cite as

Hypothalamo-pituitary-adrenal axis after a single epidural triamcinolone injection

  • Ali Iranmanesh
  • Dakshinamurty Gullapalli
  • Ravinder Singh
  • Johannes D. Veldhuis
Original Article

Abstract

Purpose

To quantify adrenocorticotropin and cortisol secretion after epidural glucocorticoid injection.

Methods

Eight men (ages 25–63 year) were studied at baseline, 1, 4, and 12 weeks after triamcinolone (80 mg) injection epidurally. Adrenocorticotropin (pg/mL) and cortisol (µg/dL) were measured every 10 min for 4 h, and after Corticotropin-releasing hormone (CRH) (1 µg/kg) injection.

Results

Epidural triamcinolone markedly suppressed: (1) pre-CRH injection ACTH (from 18 ± 3.1 to 4.8 ± 0.4: P < 0.01) and cortisol (from 12.2 ± 1.6 to 1.6 ± 0.3: P < 0.0001) at week 1, with recovery at 4 weeks, and (2) CRH-stimulated 3-h summed ACTH (from 633 ± 116 to 129 ± 10 pg/mL, P < 0.0001), and 3-h summed cortisol at week 1 (from 385 ± 29 to 56 ± 22 µg/dL, P < 0.0001) and 4 weeks (284 ± 53; P < 0.01). Serum cortisol was <18 µg/dL in eight of eight men at 4 weeks, and six of eight men at week 12. Urinary-free cortisol (µg/24 h) remained low at week 12: baseline (60 ± 6.5); week 1 (9.0 ± 1.3, P < 0.01); week 4 (36 ± 8.6) and week 12 (38 ± 4.1). Urinary cortisol/cortisone ratios rose at week 4 only. Serum triamcinolone peaked at week 1 (16/16 samples), declining at week 4 (13/16 samples) and week 12 (6/16 samples).

Limitations

Relatively small group.

Conclusion

Epidural triamcinolone suppresses unstimulated and CRH-stimulated ACTH and cortisol secretion for 1–4 weeks but urinary free cortisol ≥12 weeks. Suppression of ACTH and cortisol after glucocorticoid treatment is thus complex.

Keywords

Glucocorticoid ACTH Cortisol Human Inhibition 

Abbreviations

ACTH

Adrenocorticotropin

ANOVA

analysis of variance

CI

Confidence interval

CNS

Central nervous system

CRH

Corticotropin-releasing hormone

CSF

Cerebrospinal fluid

DM

Diabetes mellitus

HPA

Hypothalamic-pituitary-adrenal

RIA

Radioimmunoassay

SEM

Structure equation of modeling

Notes

Acknowledgements

We thank Jill Smith for support of manuscript preparation and the Mayo Immunochemical Laboratory for assistance with mass spectrometry (RJS). All authors have had access to the data and a role in writing the manuscript.

Funding

This study was funded in part by the National Institutes of Health in Bethesda, MD [R01 DK073148 (JDV)], and the Salem Research Institute of the Salem VA Medical Center (AI). The Mayo Immunochemical Laboratory provided assistance with mass spectrometry (RJS). Supported in part via R01 DK073148 (JDV) from the National Institutes of Health (Bethesda, MD), and the Salem Research Institute of the Salem VA Medical Center (AI). Contents are solely the responsibility of the authors and do not necessarily represent the official views of any federal institution.

Author Contributions

Conception and design of research (A.I., J.D.V., D.G.); performed experiments (A.I., D.G.); analyzed data (J.D.V.); interpreted results of experiments (A.I., J.D.V.); drafted manuscript (A.I., J.D.V.); prepared figures (A.I., J.D.V.); edited and revised manuscript (A.I., J.D.V.); approved final version of manuscript (A.I., D.G., R.S., J.D.V.).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no competing interests.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    P.A.N. Chrousos, M.A. Magiakou, in Glucocorticoid Therapy and Adrenal Suppression, ed. by L. de Groote, G. Chrousos, K. Dungan, K.R. Feingold, A. Grossman, J.M. Hershman, C. Koch, M. Korbonits, R. McLachlan, M. New, J. Purnell, R. Rebar, F. Singer, A. Vinik (MDText.com, Inc., South Dartmouth, MA, 2000) (Online Textbook)Google Scholar
  2. 2.
    C. Osterlund, R.L. Spencer, Corticosterone pretreatment suppresses stress-induced hypothalamic-pituitary-adrenal axis activity via multiple actions that vary with time, site of action, and de novo protein synthesis. J. Endocrinol. 208, 311–322 (2011)PubMedPubMedCentralGoogle Scholar
  3. 3.
    B. Chernow, R. Vigersky, J.T. O’Brian, L.P. Georges, Secondary adrenal insufficiency after intrathecal steroid administration. J. Neurosurg. 56, 567–570 (1982)CrossRefPubMedGoogle Scholar
  4. 4.
    C.L. Knight, J.C. Burnell, Systemic side-effects of extradural steroids. Anaesthesia 35, 593–594 (1980)CrossRefPubMedGoogle Scholar
  5. 5.
    L.C. Edmonds, M.L. Vance, J.M. Hughes, Morbidity from paraspinal depo corticosteroid injections for analgesia: cushing’s syndrome and adrenal suppression. Anesth. Analg. 72, 820–822 (1991)CrossRefPubMedGoogle Scholar
  6. 6.
    M.H. Horani, A.B. Silverberg, Secondary Cushing’s syndrome after a single epidural injection of a corticosteroid. Endocr. Pract. 11, 408–410 (2005)CrossRefPubMedGoogle Scholar
  7. 7.
    L. Manchikanti, V. Pampati, F.J. Falco, J.A. Hirsch, Assessment of the growth of epidural injections in the medicare population from 2000 to 2011. Pain Physician 16, E349–E364 (2013)PubMedGoogle Scholar
  8. 8.
    J.M. Burn, L. Langdon, Duration of action of epidural methyl prednisolone. A study in patients with the lumbosciatic syndrome. Am. J. Phys. Med. 53, 29–34 (1974)PubMedGoogle Scholar
  9. 9.
    S. Jacobs, P.T. Pullan, J.M. Potter, G.M. Shenfield, Adrenal suppression following extradural steroids. Anaesthesia 38, 953–956 (1983)CrossRefPubMedGoogle Scholar
  10. 10.
    J.F. Maillefert, S. Aho, M.C. Huguenin, C. Chatard, T. Peere, M.F. Marquignon, B. Lucas, C. Tavernier, Systemic effects of epidural dexamethasone injections. Rev. Rhum. Engl. Ed. 62, 429–432 (1995)PubMedGoogle Scholar
  11. 11.
    M. Younes, F. Neffati, M. Touzi, S. Hassen-Zrour, Y. Fendri, I. Bejia, A.A. Ben, N. Bergaoui, M.F. Najjar, Systemic effects of epidural and intra-articular glucocorticoid injections in diabetic and non-diabetic patients. Joint Bone Spine 74, 472–476 (2007)CrossRefPubMedGoogle Scholar
  12. 12.
    J.Y. Chon, H.S. Moon, Salivary cortisol concentration changes after epidural steroid injection. Pain Physician 15, 461–466 (2012)PubMedGoogle Scholar
  13. 13.
    J. Kay, J.W. Findling, H. Raff, Epidural triamcinolone suppresses the pituitary-adrenal axis in human subjects. Anesth. Analg. 79, 501–505 (1994)CrossRefPubMedGoogle Scholar
  14. 14.
    D.W. Gorski, T.L. Rao, S.N. Glisson, M. Chinthagada, A.A. El-Etr, Epidural triamcinolone and adrenal response to hypoglycemic stress in dogs. Anesthesiology 57, 364–366 (1982)CrossRefPubMedGoogle Scholar
  15. 15.
    G. Habib, A. Jabbour, J. Salman, G. Hakim, H. Haddad, The effect of epidural methylprednisolone acetate injection on the hypothalamic-pituitary-adrenal axis. J. Clin. Anesth. 25, 629–633 (2013)CrossRefPubMedGoogle Scholar
  16. 16.
    M.C. Lansang, T. Farmer, L. Kennedy, Diagnosing the unrecognized systemic absorption of intra-articular and epidural steroid injections. Endocr. Pract. 15, 225–228 (2009)CrossRefPubMedGoogle Scholar
  17. 17.
    A. Iranmanesh, D. Lawson, B. Dunn, J.D. Veldhuis, Glucose ingestion selectively amplifies ACTH and cortisol secretory-burst mass and enhances their joint synchrony in healthy men. J. Clin. Endocrinol. Metab. 96, 2882–2888 (2011)CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    K. Kovacs, S. Wagley, M.T. Quirk, O.M. Ceron, P.A. Silva, R.J. Singh, H.J. Gukasyan, J.G. Arroyo, Pharmacokinetic study of vitreous and serum concentrations of triamcinolone acetonide after posterior sub-tenon’s injection. Am. J. Ophthalmol. 153, 939–948 (2012)CrossRefPubMedGoogle Scholar
  19. 19.
    R.L. Taylor, D. Machacek, R.J. Singh, Validation of a high-throughput liquid chromatography-tandem mass spectrometry method for urinary cortisol and cortisone. Clin. Chem. 48, 1511–1519 (2002)PubMedGoogle Scholar
  20. 20.
    J.D. Veldhuis, A. Iranmanesh, F. Roelfsema, P. Aoun, P.Y. Takahashi, J.M. Miles, D.M. Keenan, Tripartite control of dynamic ACTH-cortisol dose-responsiveness by age, body mass index and gender in 111 healthy adults. J. Clin. Endocrinol. Metab. 96, 2874–2881 (2011)CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    G.M. Bright, Corticosteroid-binding globulin influences kinetic parameters of plasma cortisol transport and clearance. J. Clin. Endocrinol. Metab. 80, 770–775 (1995)PubMedGoogle Scholar
  22. 22.
    J.D. Veldhuis, D.M. Keenan, S.M. Pincus, Motivations and methods for analyzing pulsatile hormone secretion. Endocr. Rev. 29, 823–864 (2008)CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    J.H. Zar. Biostatistical analysis. 3rd edn. Prentice Hall, Upper Saddle River, NJ), 1996)Google Scholar
  24. 24.
    A.D. Sehgal, D.C. Tweed, W.J. Gardner, M.K. Foote, Laboratory studies after intrathecal corticosteroids: determination of corticosteroids in plasma and cerebrospinal fluid. Arch. Neurol. 9, 64–68 (1963)CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Ali Iranmanesh
    • 1
  • Dakshinamurty Gullapalli
    • 1
  • Ravinder Singh
    • 2
  • Johannes D. Veldhuis
    • 3
  1. 1.Endocrine and Neurology Sections, Medical ServiceSalem Veterans Affairs Medical CenterSalemUSA
  2. 2.Department of Laboratory Medicine and PathologyMayo ClinicRochesterUSA
  3. 3.Department of Medicine, Endocrine Research Unit, Mayo School of Graduate Medical Education, Clinical Translational Science CenterMayo ClinicRochesterUSA

Personalised recommendations